Quinolines derivatives as novel anticancer agents

A compound of formula (I)

• wherein:
• Rl is selected from optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heteroaromatic 5 to 9 membered ring comprising 1, 2 or 3heteroatoms independently selected from O, N, and S;
• R2 is selected from Cl, F, I, Br, C1-C6 alkyl, C1-C6 alkyl substituted with one or more halogens, C1-C6 alkoxy, hydroxy, nitro or NR7R8, NR7—(CO)—R8, NR7—(CO)—O—R8, NR7—(CO)—NR7R8, O—(CO)R7, O—(CO)—O—R7, O—(CO)—NR7R8, (CO)R7, (CO)—O—R7, (CO)—NR7R8, SO2—R7, SO2NR7R8, NR7—SO2—R8, with R7 and R8 representing independently hydrogen, C1-C6 alkyl, phenyl (optionally substituted with one or more substituent groups selected from Cl, F, I, Br, C1-C6 alkyl, C1-C6 alkyl substituted with one or more halogens, C1-C6 alkoxy, hydroxy, cyano, nitro or NR7R8) or benzyl (optionally substituted with one or more substituent groups selected from Cl, F, I, Br, C1-C6 alkyl, C1-C6 alkyl substituted with one or more halogens, C1-C6 alkoxy, hydroxy, cyano, nitro or NR7R8), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl and heteroaryl;
• Ll is selected from a bond or from optionally substituted C1-C14 alkyl(-R3), N(—R3), (CO)—O, (CO)—NR7, and O;
• n is 0, 1, 2, 3 or 4;
• and
• W is
• wherein:
• L2 is selected from a bond or from optionally substituted C1-C14 alkyl(-R3), N(—R3), (CO)—O, (CO)—NR7, and O;
• wherein R3 is selected from H, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C3-C12 cycloalkyl, and optionally substituted C3-C12 cycloalkenyl;
• and wherein R7 is as defined above;
• and
• R4 and R5 are independently selected from hydrogen, C1-C6 alkyl or phenyl (optionally substituted with one or more substituent groups selected from Cl, F, I, Br, C1-C6 alkyl, C1-C6 alkyl substituted with one or more halogens, C1-C6 alkoxy, hydroxy, cyano, nitro or NR7R8) or benzyl (with the phenyl group optionally substituted with one or more substituent groups selected from Cl, F, I, Br, C1-C6 alkyl, C1-C6 alkyl substituted with one or more halogens, C1-C6 alkoxy, hydroxy, cyano, nitro or NR7R8) or CH2—CH2-Phenyl (with the phenyl group optionally substituted with one or more substituent groups selected from Cl, F, I, Br, C1-C6 alkyl, C1-C6 alkyl substituted with one or more halogens, C1-C6 alkoxy, hydroxy, cyano, nitro or NR7R8), (CO)—R7, (CO)—OR7, (CO)—NR7R8, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, monocyclic or bicyclic heteroaryl or R4 and R5 are linked to form a heterocyclic group,
• wherein the term “optionally substituted” means optionally substituted with one or more substituents independently selected from Cl, F, I, Br, C1-C6 alkyl, C1-C6 alkyl substituted with one or more halogens, C1-C6 alkoxy, hydroxy, cyano, nitro or NR7R8 with R7 and R8 representing independently hydrogen, C1-C6 alkyl, phenyl (optionally substituted with one or more substituent groups selected from Cl, F, I, Br, C1-C6 alkyl, C1-C6 alkyl substituted with one or more halogens, C1-C6 alkoxy, hydroxy, cyano, nitro or NR7R8) or benzyl (optionally substituted with one or more substituent groups selected from Cl, F, I, Br, C1-C6 alkyl, C1-C6 alkyl substituted with one or more halogens, C1-C6 alkoxy, hydroxy, cyano, nitro or NR7R8), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl and heteroaryl;
• and any pharmaceutically acceptable salt, solvate or prodrug thereof.